Verona Pharma plc
VRNADelisted Oct 7, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657312
Verona Pharma plc was delisted on Oct 7, 2025; its insiders filed their last Form 4 on Oct 8, 2025; 243 institutions reported holding it in 13F filings for Q3 2025, worth $8.57B in total; superinvestors Duquesne Family Office and Soros Fund Management held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:52 PM ET
Revenue flow, FY2024
Where the revenue went in FY2024, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2024: $173.4M (410.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 7, 2025 | Feb 29, 2024 | Mar 7, 2023 | Jan 5, 2022 | Jan 25, 2021 |
| Revenue | $42.3M | $0 | $458.0K | $40.0M | – |
| Cost of revenue | – | $0 | $346.0K | – | – |
| Gross profit | – | $0 | $112.0K | – | – |
| Operating expenses | $196.9M | $67.6M | $75.9M | $113.3M | $74.3M |
| Research and development | $44.6M | $17.2M | $49.3M | $79.4M | $44.5M |
| Selling, general and administrative | $149.8M | $50.4M | $26.6M | $33.9M | $29.8M |
| Operating income | -$154.6M | -$67.6M | -$75.8M | -$73.3M | -$74.3M |
| Interest expense | – | $2.06M | $521.0K | $340.0K | $35.0K |
| Income tax | $10.3M | $474.0K | $253.0K | -$18.0K | $146.0K |
| Net income | -$173.4M | -$54.4M | -$68.7M | -$55.6M | -$65.1M |
| EPS, basic | $-0.27 | $-0.09 | $-0.13 | – | – |
| EPS, diluted | $-0.27 | $-0.09 | $-0.13 | – | – |
| Weighted shares, basic | 652.3M | 634.1M | 529.1M | – | – |
| Weighted shares, diluted | 652.3M | 634.1M | 529.1M | – | – |
| Margins and growth | |||||
| Gross margin | – | – | 24.5% | – | – |
| Operating margin | -365.7% | – | -16539.3% | -183.3% | – |
| Net margin | -410.2% | – | -15000.2% | -138.9% | – |
| Revenue growth, year over year | – | −100.0% | −98.9% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 7, 2025 | Feb 29, 2024 | Mar 7, 2023 | Jan 5, 2022 | Jan 25, 2021 |
| Cash and equivalents | $399.8M | $271.8M | $227.8M | $148.4M | $188.0M |
| Short-term investments | – | – | – | – | $0 |
| Accounts receivable | $31.5M | – | – | – | – |
| Inventory | $6.25M | – | – | – | – |
| Total current assets | $453.6M | $289.7M | $243.0M | $170.1M | $202.5M |
| Property, plant and equipment | $1.10M | $24.0K | $73.0K | $80.0K | $107.0K |
| Goodwill | $545.0K | $545.0K | $545.0K | $545.0K | $545.0K |
| Total assets | $474.2M | $308.1M | $259.5M | $186.6M | $204.2M |
| Accounts payable | $11.3M | $3.49M | $2.91M | $10.0M | $178.0K |
| Total current liabilities | $42.7M | $8.69M | $19.0M | $33.4M | $14.2M |
| Long-term debt | $120.3M | $48.4M | $9.77M | $4.87M | $4.63M |
| Total liabilities | $269.7M | $58.8M | $29.0M | $38.6M | $19.4M |
| Shareholders' equity | $204.6M | $249.3M | $230.5M | $148.0M | $184.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 7, 2025 | Feb 29, 2024 | Mar 7, 2023 | Jan 5, 2022 | Jan 25, 2021 |
| Operating cash flow | -$122.2M | -$50.2M | -$59.9M | -$33.3M | -$45.1M |
| Capital expenditures | $580.0K | $0 | $29.0K | $12.0K | $82.0K |
| Free cash flow | -$122.8M | -$50.2M | -$59.9M | -$33.3M | -$45.2M |
| Depreciation and amortization | $1.06M | $677.0K | $636.0K | $629.0K | $623.0K |
| Stock-based compensation | $41.2M | $19.0M | $14.1M | $25.4M | $22.2M |
| Investing cash flow | -$580.0K | $0 | -$29.0K | -$12.0K | $9.71M |
| Financing cash flow | $250.8M | $92.9M | $140.8M | -$6.12M | $192.3M |
| Net change in cash | $128.0M | $43.9M | $79.4M | -$39.6M | $157.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 97.6% | – | 3083.2% | 63.6% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 23, 2025 | 681.1M | +5.0% | SEC |
| Feb 24, 2025 | 679.8M | +5.2% | SEC |
| Oct 28, 2024 | 654.6M | +2.4% | SEC |
| Aug 2, 2024 | 649.9M | +2.2% | SEC |
| May 2, 2024 | 648.7M | +2.0% | SEC |
| Feb 23, 2024 | 646.5M | +2.3% | SEC |
| Oct 27, 2023 | 639.5M | +5.7% | SEC |
| Jul 27, 2023 | 635.9M | +30.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.